Karyotype evolution in response to chemoradiotherapy and upon recurrence of esophageal adenocarcinomas
Karen van der Sluis,
Johanna W. van Sandick,
Willem J. Koemans,
Tom van den Bosch,
Annegien Broeks,
Dennis Peters,
Iris M. Seignette,
Christian R. Rausch,
Erik van Dijk,
Petur Snaebjornsson,
José G. van den Berg,
Nicole C.T. van Grieken,
Bauke Ylstra,
Beatriz Carvalho,
Daniël M. Miedema,
Liudmila L. Kodach
Affiliations
Karen van der Sluis
Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Johanna W. van Sandick
Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Willem J. Koemans
Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Tom van den Bosch
Amsterdam UMC Location University of Amsterdam, Cancer Center Amsterdam & Amsterdam Gastroenterology Endocrinology Metabolism, Center for Experimental and Molecular Medicine, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands
Annegien Broeks
Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands
Dennis Peters
Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands
Iris M. Seignette
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Christian R. Rausch
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Erik van Dijk
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Petur Snaebjornsson
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Faculty of Medicine, University of Iceland, Reykjavik, Iceland
José G. van den Berg
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Nicole C.T. van Grieken
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Bauke Ylstra
Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Beatriz Carvalho
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Daniël M. Miedema
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Corresponding author
Liudmila L. Kodach
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Corresponding author
Summary: The genome of esophageal adenocarcinoma (EAC) is highly unstable and might evolve over time. Here, we track karyotype evolution in EACs in response to treatment and upon recurrence through multi-region and longitudinal analysis. To this end, we introduce L-PAC (low-purity inference of absolute copy-number alterations [CNAs]), a bio-informatics technique that allows inference of absolute CNAs of low-purity samples by leveraging the information of high-purity samples from the same cancer. Quantitative analysis of matched absolute CNAs reveals that the amount of karyotype evolution induced by chemoradiotherapy (CRT) is predictive for early recurrence and depends on the initial level of karyotype intra-tumor heterogeneity. We observe that CNAs acquired in response to CRT are partially reversed back to the initial state upon recurrence. Hence, CRT alters the fitness landscape to which tumors can adjust by adapting their karyotype. Together, our results indicate that karyotype plasticity contributes to the therapy resistance of EACs.